Regeneron Pharmaceuticals (REGN) has seen a significant increase in stock value, with shares rising 41% over the past six months, surpassing the industry growth of 22.4%. The stock reached a 52-week high of $792.77 on December 24, 2025.
Key developments include the FDA’s approval of Eylea HD for macular edema following retinal vein occlusion, with dosing options of up to every eight weeks. Additionally, Regeneron’s oncology drug, Libtayo, generated $1.03 billion in sales during the first nine months of 2025, marking a 21% increase from the previous year. Regeneron is also managing competitive pressures from Roche’s Vabysmo in the eye treatment market, necessitating the introduction of Eylea HD.
Overall, Regeneron’s advancements, including the recent approvals and sales growth in its oncology and ophthalmology franchises, position it favorably in the market despite competitive challenges.
